Royalty Report: Drugs, Diagnostic, Biotechnology – Collection: 27424


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Diagnostic
  • Biotechnology
  • Diagnostic Substances
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 27424

License Grant
The Licensor, a university, grants to the Licensee a non-exclusive license under the Licensed Patent and Technical Information with the right to grant  sub-licenses,  to make,  have made, use and sell Licensed Product in the United States.

Licensed Product is an in-vitro diagnostic kit known under the trade name Gonostat which detects the presence of gonococchal DNA by using genetic transformation technology and a mutant strain of Neisseria gonorrhea.

License Property
The kit incorporates test methodology for the laboratory diagnosis and test strain of neisseria gonorrhea, covered by U.S. Patent No. 4,446,230 issued  May 1, 1984  entitled  'Test  Method  for the  Laboratory  Diagnosis  of Gonorrhea and Test Strain of Neisseria Gonorrhea'.  Neisseria gonorrhea, also known as gonococci (plural), or gonococcus (singular), is a species of Gram-negative coffee bean-shaped diplococci bacteria responsible for the sexually transmitted infection gonorrhea.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 29096

License Grant
The Licensor,not-for-profit corporation, grants a non-exclusive subLicenses to such patents to the Licensee in the field of commercial diagnostic testing services for detection of UGT1A1 in humans effective April 14, 2006. The Licensee will pay an upfront fee and royalties.

The Licensor Licensed certain patents related to UGT1A1, from a University pursuant to a License Agreement dated November 18, 2005.

License Property
UGT1A1 is a hepatic enzyme primarily responsible for conjugation of bilirubin. UGT1A1 also catalyzes the glucuronidation of SN-38, the active metabolite of irinotecan and the main source of treatment-related toxicity.

US Issued Pat App No. 08/423,641, filing date 04/17/95, Patent No. 5,786,344
US Issued Pat App No. 09/251,274, filing date 02/16/99, Patent No. 6,395,481
US Issued Pat App No. 10/061,693, filing date 02/01/02, Patent No. 6,472,157

Field of Use
Field means commercial diagnostic testing services for detection of UGT1A1 in humans. Field does not include the research, development, manufacture, marketing, or sale of therapeutic products. Commercial diagnostic testing services shall include, but not be limited to, in-house laboratory tests pursuant to CLIA, clinical trials testing, and the manufacture, use and sale of diagnostic kits.

IPSCIO Record ID: 5760

License Grant
The University hereby grants the following license during the Term in the Territory: A nonexclusive, fee- and royalty-bearing license, including the right to grant sublicenses, under the Intellectual Property, to make, have made, sell, offer for sale, use, and import Licensed Products in the Field.
License Property
The University is the owner of certain Patent Rights, Tangible Research Property and Technical Information relating to polypeptides and antibodies useful for the diagnosis and treatment of pathogenic Neisseria and other organisms having Type IV pilin.

We are using this technology in the development of antibiotics against gram-negative pathogens.  These bacteria utilize structures called pili to adhere to target tissue, and we plan to exploit the assembly and export of these essential infective structures as novel anti-infective targets.

Patent Rights: US Patent No. 5,834,591 and all foreign counterparts, continuations, continuations-in-part, divisions, extensions, reexamination and reissues thereof, which trace their earliest priority filing date by unbroken lineage to this patent and its parent applications.

Field of Use
Field: Human and veterinary antimicrobial therapeutic and prophylactic compounds and vaccines.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.